Keros Therapeutics, Inc.
KROSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Keros Therapeutics, Inc. focuses on Biotechnology services and products. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the. Valued at $209.2M, KROS is a micro-cap name in its sector. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Market Cap
$209.2M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-1.89
EPS (TTM)
$-2.53
EPS (Fwd)
$-5.59
ROE
-16.8%
ROA
-12.2%
Cash
$281.5M
Total Debt
$16.3M
Free CF
-$37.7M
52W Change
-23.0%
Annual Financials
Cash vs Debt
Where KROS stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, KROS finished 15.52% below its 150-day moving average ($14.24) and 18.00% below its 200-day moving average ($14.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KROS overbought or oversold?
At the July 10, 2026 close, KROS's RSI(14) was 71.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Keros Therapeutics, Inc. holds $281.5M in cash against $16.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$37.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -16.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing KROS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.